Szechuan lovage

Szechuan Lovage (Ligusticum chuanxiong Hort.): A Comprehensive Reference

1. Identity

1.1 Botanical and Taxonomic Classification

Szechuan lovage is the dried rhizome of Ligusticum chuanxiong Hort. (family Apiaceae, also known as Umbelliferae). It is a perennial herb — also known as Chuanxiong — grown mainly on China's Yun-Gui-Chuan plateau, capable of reaching up to two feet in height. The full accepted botanical name is Ligusticum chuanxiong S.H.Qiu, Y.Q.Zeng, K.Y.Pan, Y.C.Tang and J.M.Xu (Apiaceae; including the horticultural variety Ligusticum chuanxiong Hort.), with the synonym Conioselinum anthriscoides (H.Boissieu) Pimenov and Kljuykov, as adopted by the World Checklist of Vascular Plants. Earlier taxonomic literature also applied the names Ligusticum wallichii Franchat and Ligusticum striatum DC to the same plant. The herb belongs to the carrot family (Apiaceae) and is closely related to Western lovage.

The plant is a perennial herbaceous species in the Apiaceae (Umbelliferae) family, growing 40–70 cm tall, with upright, cylindrical, hollow stems bearing conspicuous swollen nodes and compound leaves resembling those of celery or Cnidium, dark green with a distinctive aromatic fragrance. Small white flowers appear in compound umbels during summer; the plant rarely sets viable seed under cultivation and is instead propagated vegetatively from rhizome segments.

1.2 Common Names and Synonyms

• Chinese: 川芎 (Chuān Xiōng); historical name: Xiongqiong (雄穷)
• English: Szechuan lovage, Sichuan lovage root, Chuanxiong
• TCM pharmacopoeia: Rhizoma Ligustici Chuanxiong; Rhizoma Chuanxiong; Chuanxiong Rhizoma
• Botanical synonyms: Ligusticum wallichii Franchat; Ligusticum striatum DC; Conioselinum anthriscoides

1.3 Plant Morphology and the Medicinal Part

The medicinal part is the rhizome, which forms an irregularly knotted, fist-shaped mass 2–7 cm in diameter, with a yellowish-brown, rough surface bearing multiple parallel ridges (the "node rings"). Authentic Sichuan Chuan Xiong can be distinguished by its fist-like knotted shape with prominent node rings, a strong characteristic aroma, and a distinctive wavy cambium ring on cross-section. Small white flowers occur July through August, with fruit appearing in September; most of the medicinal herb comes from cultivation, and gathering of the roots and rhizomes takes place in May.

1.4 Geographical Origin and Cultivation

Also known as Rhizoma Ligustici Chuanxiong, the plant is mainly produced in Sichuan, Guizhou, and Yunnan provinces in China. Apart from China, the rhizome is also used in Singapore, Malaysia, the European Union, and the United States of America.

1.5 Common Preparations and Dosage Forms

Excavation of medicinal lovage typically occurs in May; after removal, the mud is cleaned off, the material is dried in the sun, and the fibrous roots are discarded. The rhizome is then sliced for use, either unprocessed or stir-fried with wine. Rhizoma Chuanxiong is usually processed before clinical use to enhance therapeutic efficacy; four principal processing methods include stir-frying, steaming, stir-frying with rice wine, and steaming with rice wine.

Nine dosage forms have been reported in the literature, including powders, pills, concentrated pills, drip pills, tablets, granules, bagged tea, oral liquid, and soft capsules; the Chinese Pharmacopoeia 2020 edition includes six dosage forms: powders, pills, concentrated pills, tablets, granules, and bagged tea. In clinical medicine, Chuanxiong has also been formulated into injectable preparations. In clinical treatment, Chuanxiong has been made into a variety of Chinese medicines, including ligustrazine injection, Xuefu Zhuyu Granules, and Chuanxiong Chatiao San.

2. Traditional and Historical Use

2.1 Earliest Records

Szechwan lovage rhizome has a long history of medicinal uses. The earliest name for the herb was "Xiongqiong," recorded in The Classic of Mountains and Seas compiled in China during the Pre-Qin Dynasty (estimated from 476 BC to 221 BC), which stated that "the grasses were many peonies and Xiongqiong." It has been used by Chinese medicinal physicians for more than 2,000 years; its pharmacological effect was first mentioned in the Shen Nong Ben Cao Jing, a compilation of information regarding Chinese herbs dating back to antiquity. In the Shennong Bencao Jing (Shennong's Classic of Materia Medica), it was listed as a top-grade herb for treating headaches, strokes, and menstrual issues; the Mingyi Bielu noted its ability to clear wind-related symptoms and stagnant blood.

2.2 Role in Traditional Chinese Medicine (TCM)

Chuan Xiong is one of Chinese medicine's most important herbs for promoting healthy blood circulation and relieving pain, especially headaches and menstrual pain; nicknamed the "Qi herb within the Blood," it uniquely combines the ability to move both blood and Qi, making it a cornerstone of many classical formulas for women's health and pain management. Ligusticum is considered one of the 50 fundamental herbs in Traditional Chinese Medicine.

In traditional Chinese medicine, ligusticum has pungent and warm properties, and is associated with the Liver, Gallbladder, and Pericardium meridians; its main functions are to promote the flow of blood and Qi, dispel wind, and relieve pain. In TCM, Szechuan lovage is used to stimulate blood flow; the root has been used to treat cardiovascular ailments, menstrual issues, cysts, and clots. Considered a "warming" herb used for cold or yin conditions, it is thought to have an effect on the gallbladder, liver, and pericardium, and as these organs are considered related to the emotions, the herb has also been used to balance the emotions.

In China, the herb is often used to treat gynecological diseases, such as dysmenorrhea, amenorrhea, dystocia, and lochia, and it is also applied to treat ischemic diseases such as dizziness, headache, and migraine. Chuan Xiong is the leading Chinese herb for headache and migraine of any type — Wind-Cold, Wind-Heat, Blood stasis, or Liver Yang headaches; it also treats irregular menstruation and dysmenorrhea from Blood stasis, chest pain from Heart Blood stasis, and rheumatic joint pain (Bi syndrome). It is one of the most frequently used blood-invigorating and Qi-moving herbs in the Chinese Materia Medica.

2.3 Classical Formulas

The classic prescription Chuanxiong Chatiao San (CXCT) has a history of more than 1,000 years for treating migraine; it consists of eight herbs: Ligusticum chuanxiong, Angelicae Dahuricae Radix, Notopterygium incisum, Asarum sieboldii, Radix Saposhnikoviae Divaricatae, Nepeta cataria, Mentha haplocalyx, and Glycyrrhiza uralensis. Chuan Xiong is a vital ingredient in Buyanghuanwu decoction, Houshiheisan, and Naoxintong capsules — all classic TCM prescriptions that have demonstrated efficacy in treating cardiovascular and CNS diseases.

Chuanxiong is also used in the TCM space as Suxiao Jiuxin Wan, an oral medication composed of Ligusticum chuanxiong and Borneolum syntheticum, commonly used as fast-acting angina relief as well as a daily-use angina prevention medication.

Long used by the Chinese as a medicinal herb, Ligusticum chuanxiong is also used in cooking and as a fragrance in soaps and cosmetics.

3. Key Constituents and Active Compounds

3.1 Overview of Chemical Complexity

More than 263 substances have been isolated from different parts (rhizomes, fibrous roots, and aboveground parts) of Chuanxiong, including volatile oils, organic acids, phenolic acids, phthalides, alkaloids, polysaccharides, ceramides, cerebrosides, and terpenoids. More than 80 compounds of various structural types have been identified, including tetramethylpyrazine (TMP), ligustilide, senkyunolide A, and ferulic acid; research on active components mainly focuses on phthalides, alkaloids, and phenolic acids.

Over 100 chemical metabolites have been isolated from Chuanxiong, including phthalides, terpenes and their enol derivatives, alkaloids, polysaccharides, and organic acids and their ester derivatives.

3.2 Phthalide Lactones

Z-Ligustilide is the most abundant phthalide and is considered the principal bioactive volatile constituent. Ligustilide is the principal smooth muscle relaxant responsible for effects on blood vessels and the uterus. Pharmacokinetic studies have shown that Z-ligustilide has poor oral bioavailability in rats due to severe first-pass metabolic reactions; nevertheless, new evidence suggests that Z-ligustilide has a wide range of pharmacological properties, including anticancer, anti-inflammatory, antioxidant, and neuroprotective activities.

Other identified phthalides include senkyunolide A, senkyunolide I, senkyunolide H, senkyunolide J, senkyunolide D, senkyunolide F, senkyunolide M, senkyunolide Q, neocnidilide, levistolide A, E-butylidenephthalide, and E-ligustilide. Analysis has unequivocally identified vanillin, ferulic acid, senkyunolide I, senkyunolide H, senkyunolide A, coniferyl ferulate, Z-ligustilide, neocnidilide, and 3-butylidenephthalide by comparison with authentic standards. Ferulic acid, senkyunolide I, senkyunolide H, senkyunolide A, Z-ligustilide, and levistolide A are the components commonly used as chemical markers for quality control.

3.3 Alkaloids — Tetramethylpyrazine (TMP / Ligustrazine)

Tetramethylpyrazine (ligustrazine, TMP) is a natural compound isolated from Ligusticum wallichii (Chuan Xiong); it was first isolated in 1957 and has been increasingly studied for its action on myocardial and cerebral infarction since the 1970s. The content of ligustrazine in Chuanxiong is only 0.01–0.02%, and its chemical structure is that of a pyrazine derivative.

TMP is an active component of Chuanxiong that effectively crosses the blood-brain barrier (BBB). Several studies have shown that TMP can exhibit multiple biopharmacological activities, such as inhibition of platelet aggregation, oxidative stress, inflammation, and apoptosis. TMP is quickly absorbed in the human body with an absorption half-life of 0.15 h, with time to peak concentration in the blood of 0.51 h; TMP is then rapidly and widely distributed in vivo, with a plasma protein binding rate of 64.64%.

3.4 Phenolic Acids — Ferulic Acid

Ferulic acid has shown antioxidant properties through its interaction with 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical, acting as a key antioxidant metabolite in Chuanxiong; due to its abundance, ferulic acid is frequently used as a quality control marker. According to the 2020 edition of the Chinese Pharmacopoeia, the ferulic acid content in dried Chuanxiong should not be less than 0.01%. Phenolic compounds (ferulic acid), phthalide (ligustilide), and alkaloids (ligustrazine) are the three main groups of constituents and are the main active components of Ligusticum chuanxiong, especially in the treatment of neurovascular and cardiovascular diseases.

3.5 Polysaccharides

Over 100 metabolites have been isolated and identified from Chuanxiong, classified into nine major classes; key bioactive compounds include senkyunolide A, ligustilide, tetramethylpyrazine (TMP), and Ligusticum CX polysaccharides (LCP). Polysaccharides represent an emerging area of research interest within this plant's chemical profile, though mechanistic studies remain predominantly preclinical.

3.6 Metabolite Absorption and Biotransformation

In pharmacokinetic studies using HPLC-ESI-MS/MS methods to identify absorbed components and metabolites in rat plasma after oral administration of Rhizoma Chuanxiong decoction, a total of 25 compounds were detected in dosed rat plasma; 13 compounds were absorbed into rat plasma in prototype form, identified as ferulic acid, senkyunolide J, senkyunolide I, senkyunolide D, senkyunolide F, senkyunolide M, senkyunolide Q, senkyunolide A, E-butylidenephthalide, E-ligustilide, neocnidilide, Z-ligustilide, and levistolide A. In addition, 12 conjugated metabolites — including senkyunolide I-related, senkyunolide J-related, and butylidenephthalide-related metabolites — were identified; the main metabolic reactions of phthalides were conjugation with glutathione, cysteine, glucuronic acid, and sulfuric acid.

4. Mechanisms of Action

4.1 Antiplatelet and Anticoagulant Activity

The active ingredient ligustrazine can dilate coronary arteries, increase coronary blood flow, improve myocardial blood oxygen supply, and reduce myocardial oxygen consumption; it can reduce platelet surface activity, inhibit platelet agglutination, and prevent thrombus formation. Ligustrazine is well studied for its multiple significant biological functions, including inhibiting apoptosis, dilating blood vessels, protecting vascular endothelial cells, immune regulation, eliminating oxygen free radicals, improving cerebral ischemia, inhibiting platelet aggregation, and promoting angiogenesis. TMP can inhibit platelet aggregation, depress blood viscosity, and ameliorate microcirculation, which represents an important mechanism for treating cardiovascular and cerebrovascular diseases.

4.2 Vasodilation and Cardiovascular Effects

Studies on mechanisms in human vessels suggest that the inhibitory effect on vasoconstriction in human arteries is mainly mediated by tetramethylpyrazine — the key component of Chuanxiong. Emerging experimental studies and clinical trials have demonstrated that TMP prevents atherosclerosis as well as ischemia-reperfusion injury; the cardioprotective effects of TMP are mainly related to its antioxidant, anti-inflammatory, and calcium-homeostasis effects.

4.3 Anti-Inflammatory Signaling

Ligusticum chuanxiong exhibits anti-inflammatory biological activities by modulating several signaling pathways, specifically the NF-κB, Nrf2, protein kinase, and caspase-3 pathways. Through the integration of TCM theory and modern pharmacological research, the diverse pharmacological effects of Chuanxiong have been elucidated, particularly its anti-inflammatory and antioxidant properties, with recent studies making significant progress in understanding its chemical metabolites, pharmacological effects, pharmacokinetics, and safety profiles.

4.4 Neuroprotective Mechanisms

TMP exerts neuroprotective effects by inhibiting calcium-ion overload, inhibition of inflammatory response, promotion of blood-brain barrier (BBB) repair, enhancement of synaptic plasticity, and inducing recovery of neurovascular units. Ischemic stroke triggers a complex cascade including excitotoxicity, calcium overload, oxidative stress, and subsequent apoptosis and neuroinflammation; TMP can block multiple events of this injury cascade to provide protection.

One documented mechanism in Alzheimer's disease research involves reversal of tau hyperphosphorylation and promotion of its degradation through the lysosomal pathway, thereby mitigating tau-mediated intracellular transport impairment, axonal and synaptic damage, and neuronal death; the primary active metabolites identified in this process include neocnidilide, ferulic acid, Z-ligustilide, and butylidene phthalide.

4.5 Antioxidant Activity

Oxidative stress and inflammation, which can induce somatic cell apoptosis, are the main factors associated with an abundance of diseases whose progression can be reversed by Ligusticum chuanxiong. Ferulic acid's direct free-radical scavenging at the DPPH radical is one of the most characterized antioxidant pathways. The possible mechanism of anti-aging effects involves promoting the expression of related antioxidant pathway genes, increasing the activity of antioxidant enzymes, and reducing the accumulation of reactive oxygen species (ROS), which is dependent on DAF-16 and HSF-1; specifically, activation of antioxidase-related genes (sod-3 and sod-5) and heat shock protein genes (hsp-16.1 and hsp-70) consequently ameliorates proteotoxicity related to amyloid-beta (Aβ) aggregation.

4.6 Smooth Muscle Relaxation

Ligustilide is the principal smooth muscle relaxant, responsible for the herb's effects on both blood vessels and the uterus. Metabolites from Chuanxiong exhibit multiple pharmacological activities including vasodilation, blood circulation enhancement, antiplatelet aggregation, antioxidant, and anti-inflammatory effects; notably, some metabolites such as ligustilide have been clinically applied in the treatment of cardio-cerebral vascular diseases (CCVDs).

5. Scientific Evidence by Area of Use

5.1 Migraine and Headache

Clinical/Human Evidence

Based on the literature review, Chuanxiong formulae are the most common Chinese classical and/or patent prescriptions for treating headache both in ancient and modern times.

A 2018 systematic review and meta-analysis published in Frontiers in Pharmacology assessed the evidence specifically from high-quality RCTs. English and Chinese electronic databases were searched from their inceptions until March 2017; methodological quality was assessed by the Cochrane Collaboration risk of bias tool, and RCTs with a Cochrane risk of bias score ≥4 were included in the analyses. Nineteen RCTs with 1,832 participants were identified. Meta-analysis indicated that Chuanxiong formulae could reduce frequency, duration, days, and pain severity of migraine and improve the total clinical efficacy rate (P<0.05); adverse event monitoring was reported in 16 out of the 19 studies.

A separate systematic review and meta-analysis of the specific formula Chuanxiong Chatiao San (CXCT) — a prescription containing Ligusticum chuanxiong as the primary herb — examined RCTs from January 2000 to February 2019. A total of 3,307 patients were included across 37 articles; meta-analysis showed that CXCT significantly increased the total efficiency rate compared with Western medicine treatment (P<0.00001); when CXCT was combined with Western medicine, the result was also P<0.00001. CXCT significantly reduced adverse events compared with Western medicine (P<0.00001). VAS scores, number of migraine episodes, and time of headache duration were all significantly reduced (P<0.00001), and platelet function and blood rheology levels improved through a significant decrease in 5-HT and β-EP.

A randomized, double-blind, placebo-controlled trial investigated Chuanxiong Qingnao Granule (CQG), a Chinese patent medicine containing Chuanxiong, as a migraine treatment. This randomized, double-blind, placebo-controlled trial randomly assigned migraineurs to either CQG treatment or placebo; the whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up. A total of 346 migraineurs completed the research and were included in the intention-to-treat analyses; response rates differed significantly between the treatment and control groups (71.5% vs. 12.1% at week 12 and 83.1% vs. 3.4% at week 24). Attack frequency, days of headache attack, VAS, Fatigue Severity Scale, HAMD, and MIDAS scores decreased at week 12 in both groups, with significantly greater reduction in the treatment group (P<0.001). No severe adverse events were observed.

A separate multicenter, double-blind, placebo-controlled trial examined ChuanXiong Ding Tong Herbal Formula Granule (CXDT-HFG) in migraine patients with "the Syndrome of Liver Wind and Blood Stasis." 150 migraine patients were recruited and randomly assigned in a double-blind, placebo-controlled study to receive CXDT-HFG (n=99) plus necessary analgesics, or placebo (n=51) plus necessary analgesics for 16 weeks (12 weeks' intervention and 4 weeks' follow-up); outcome measures included migraine days, frequency of migraine attacks, analgesic consumption, responder proportions, and VAS pain scores.

Evidence Appraisal

The body of human evidence for Chuanxiong-containing formulae in migraine is extensive, with multiple meta-analyses of RCTs producing consistent positive signals. However, nearly all clinical studies involve multi-herb formulas rather than isolated Chuanxiong, making attribution of effect to the single herb difficult. Many studies are conducted in China and published in Chinese journals, and the systematic reviews note limitations in blinding and allocation concealment quality across the primary studies. Overall, the evidence is promising but not definitive for Chuanxiong-containing formulae, and insufficient for the isolated rhizome as a single agent in migraine.

5.2 Cardiovascular and Cerebrovascular Disease

Pharmacological Background

Chuanxiong has long been used in China to treat cardiovascular diseases including coronary heart disease, hypertension, arrhythmia, heart failure, dilated cardiomyopathy, dyslipidemia, and myocarditis. The benefits are attributed to its vasodilating, anti-inflammatory, anticoagulant, free radical-scavenging, and microcirculatory effects. The herb demonstrates significant pharmacological effects in treating CCVDs, such as atherosclerosis, myocardial and cerebral ischemia-reperfusion injury, and hypertension.

Clinical/Human Evidence — TMP and Cerebral Infarction

A meta-analysis of the clinical effectiveness and safety of ligustrazine (TMP) in cerebral infarction searched CNKI (1979 to 30 June 2016), VIP, Cochrane Library, Medline, PubMed, and Academic Search Premier using terms including "cerebral infarction" AND "ligustrazine" or "tetramethylpyrazine" or "TMP," restricted to RCTs. Ligustrazine is well studied for its multiple significant biological functions, including inhibiting apoptosis, dilating blood vessels, protecting vascular endothelial cells and immune regulation, eliminating oxygen free radicals, improving cerebral ischemia, inhibiting platelet aggregation, and promoting angiogenesis. Cellular experiments have demonstrated that TMP reduces neuronal death induced by oxygen-glucose deprivation, and its efficacy has been validated in clinical trials.

The pharmacological effects of TMP on the cardiovascular system have attracted great interest; emerging experimental studies and clinical trials have demonstrated that TMP prevents atherosclerosis as well as ischemia-reperfusion injury. In the past decades, researchers have explored other pharmacological capabilities of TMP in various diseases, such as coronary heart disease, diabetes, cancers, and liver injury; laboratory study has verified the regulation ability of this agent in multiple molecular targets, such as anti-inflammation, antioxidant, antiplatelet, and antiapoptosis.

Key findings across reviewed literature show that TMP has various pharmacological effects in the treatment of many cardio-cerebrovascular diseases, such as atherosclerosis, myocardial and cerebral ischemia, reperfusion injury, and hypertension.

Evidence Appraisal

TMP/ligustrazine, isolated from Chuanxiong, has been studied in clinical trials specifically for cerebrovascular conditions including stroke, and the overall direction of evidence is positive. However, most human-level data come from Chinese clinical trials of variable methodological quality, and large-scale, rigorously controlled, independently replicated trials using Western regulatory standards remain limited. Much mechanistic evidence remains at the preclinical (animal or cell) level. The clinical evidence for TMP is stronger than that for the whole herb extract for these conditions.

5.3 Ischemic Stroke and Neuroprotection

TCM, renowned for its multi-component and multi-target approaches, has been utilized for centuries in China and other countries to treat ischemic stroke, with Chuanxiong being one of the most widely used and ancient medicinal herbs from Sichuan. Ligustilide, a phthalide-derived bioactive compound abundantly found in Ligusticum chuanxiong, has attracted increasing attention for its potential therapeutic benefits in ischemic stroke; however, its clinical applications remain limited, and the comprehensive preclinical evidence regarding its efficacy and mechanisms of action is still under investigation.

Ligusticum chuanxiong Hort is a famous ethnomedicine in Asia known for its excellent output on stroke treatment; borneol usually acts as an assistant for reducing permeability of the blood-brain barrier (BBB) after stroke.

Evidence Appraisal

Evidence for stroke comes primarily from animal models and mechanistic studies of isolated compounds. Over the past two decades, TMP has been demonstrated, in both animal experiments and clinical practice, to alleviate ischemic brain injury. Human clinical evidence for the whole-herb preparation in stroke is limited, and the findings are largely embedded in multi-ingredient TCM formulas, which confounds attribution.

5.4 Cholesterol and Lipid Modulation

Ligusticum chuanxiong plays an active role in the prevention and therapy of atherosclerosis, which decreases the levels of serum cholesterol, lowers LDL density lipoprotein, relieves the extent of atherosclerosis, and reduces the red cell deformability in rabbits subjected to experimental atherosclerosis. Oral administration of Ligusticum chuanxiong at an equivalent dosage of 30 times to patients for 90 days significantly lowered serum total cholesterol (TC) and triglyceride (TG) levels. This particular human study cited here is preliminary, lacked rigorous blinding and control details per the sources reviewed, and should be interpreted with caution.

5.5 Anti-Inflammatory, Antioxidant, and Antiapoptotic Effects

Ligusticum chuanxiong is widely used in clinical settings to treat headaches, blood extravasation, and arthritis; recent studies demonstrate that it possesses versatile pharmacological functions, including antiatherosclerosis, antimigraine, antiaging, and anticancer properties. Its protective effect on D-galactose-induced liver and kidney injury is potentially linked with alleviation of oxidative stress and inflammatory response; these functions propose the possible use of Ligusticum chuanxiong as a treatment for a range of oxidative stress- and inflammation-associated diseases, including atherosclerosis, migraine, and hepatic fibrosis.

Evidence Appraisal

Anti-inflammatory and antioxidant evidence is robust at the in vitro and animal levels, with multiple pathways (NF-κB, Nrf2, caspase cascades) clearly described. Direct human clinical evidence for these specific mechanisms as therapeutic endpoints is limited, and translation from animal models to verified clinical outcomes remains to be fully established.

5.6 Gynecological Applications

In traditional Chinese medicine, the root has been used to treat cardiovascular ailments, menstrual issues, cysts, and clots. Chuanxiong has been used to protect against ischemic injury, enhance immunity, and treat menstrual cramps and diabetes. Ferulic acid, one of the predominant phenolic constituents, shares structural and pharmacological properties with other phytoestrogen-related compounds and has been examined for its effects on uterine smooth muscle, though clinical trials specific to dysmenorrhea using isolated Chuanxiong are not well documented in the peer-reviewed literature accessed for this article.

5.7 Neuropathic Pain

Modern pharmacological studies have shown that Ligusticum chuanxiong Hort has analgesic, anti-inflammatory, antioxidant, antitumor, anti-coagulation, anti-depression, anti-aging, anti-atherosclerosis, and cardiac function-improving effects. Network pharmacology analyses have investigated the herb's potential function and mechanism in the treatment of neuropathic pain, though mechanistic clarity in human subjects is not yet established.

5.8 Alzheimer's Disease and Cognitive Function

TMP, a widely used therapeutic agent for ischemia/reperfusion-induced brain injury, has been associated with only two tau-related targets, suggesting limited therapeutic relevance in tau pathology-based Alzheimer's disease; however, compared to the control group, the TMP-related group exhibited significant improvements in learning and memory abilities in transgenic AD mice, along with reduced levels of amyloid-beta and tau phosphorylation in the brain. Research in Caenorhabditis elegans demonstrates antioxidant, anti-aging, and neuroprotective activities of Chuanxiong rhizome, providing a pharmacological basis for developing functional foods and drugs to relieve the symptoms of aging and Alzheimer's disease.

Evidence Appraisal

Evidence for Alzheimer's disease and cognitive aging is entirely preclinical (transgenic animal models and invertebrate models). There are no published human clinical trials of Chuanxiong or its isolates for Alzheimer's disease that were identified in the authoritative sources reviewed here.

6. Body Systems and Health Areas

The herb has significant clinical relevance in relation to human diseases of the cardiocerebrovascular system, nervous system, respiratory system, digestive system, and urinary system. The primary areas of documented pharmacological interest are:

• Cardiovascular system: Vasodilation, antiplatelet aggregation, lipid-lowering, anti-atherosclerosis, protection from ischemia-reperfusion injury.
• Cerebrovascular system: Improvement of cerebral microcirculation, neuroprotection in ischemic stroke, blood-brain barrier support.
• Nervous system: Migraine and headache prevention/treatment, analgesic effects, Alzheimer's disease research (preclinical only), neuropathic pain (preclinical/mechanistic).
• Reproductive system (TCM): Dysmenorrhea, amenorrhea, menstrual irregularities, dystocia, post-partum blood stasis.
• Musculoskeletal: Joint pain (Bi syndrome), trauma healing.
• General: Antioxidant, anti-inflammatory, antiapoptotic activities relevant across organ systems.

A great deal of pharmacological research has been done, which mainly focuses on cardiovascular and cerebrovascular effects, antioxidation, neuroprotection, antifibrosis, antinociception, anti-inflammation, and antineoplastic activity.

7. Dosage Forms and Dosages Reported in Studies

Nine dosage forms have been reported in the literature, including powders, pills, concentrated pills, drip pills, tablets, granules, bagged tea, oral liquid, and soft capsules. The Chinese Pharmacopoeia 2020 edition formally includes six of these: powders, pills, concentrated pills, tablets, granules, and bagged tea.

The following dosages and formats have been reported in peer-reviewed sources:

• In the CXDT-HFG migraine trial, 150 migraine patients received a Chuanxiong-containing herbal formula granule for 16 weeks (12 weeks' intervention and 4 weeks' follow-up), with necessary analgesics permitted.
• The experimental drug CXDT-HFG included Chuanxiong Rhizoma (Chuanxiong) at 12 g per formula.
• In the Suanzaoren decoction — one classical TCM formula containing Chuanxiong — the prescribed amount of Rhizoma Chuanxiong is 5 g, alongside other herbs including Semen Ziziphi Spinosae 18 g, Poria 10 g, Rhizoma Anemarrhenae 10 g, and Radix Glycyrrhizae 3 g.
• In an animal study of TMP for neuroprotection, rats received intraperitoneal TMP at 40 mg/kg for 3 days prior to middle cerebral artery occlusion/reperfusion surgery and continued for 14 days post-surgery. (This is an animal dose, not a human dose.)
• In an ischemic stroke animal study, rats were treated with LCH at 0.1 g/kg and/or borneol at 0.08 g/kg. (This is an animal dose, not a human dose.)
• Oral administration of Ligusticum chuanxiong at an equivalent dosage of 30 times to patients for 90 days was studied in the context of lipid-lowering effects.
• In the Chuanxiong Qingnao Granule RCT, the whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up period.

Current chemical markers in pharmacopoeias or monographs for the quality assessment of Szechwan lovage rhizome are not well characterized or specifically characterized, nor do they fully reflect the medicinal efficacy of the herb, resulting in quality not being effectively controlled. This limits the standardization of dosages across product types.

8. Safety, Contraindications, and Drug Interactions

8.1 Contraindication in Pregnancy

Chuan Xiong is contraindicated in pregnancy because blood-invigorating herbs can stimulate uterine contraction and threaten the pregnancy. This is one of the most consistently noted safety concerns in TCM literature and has pharmacological plausibility given the documented uterotonic and smooth-muscle-relaxant actions of ligustilide.

8.2 Bleeding Risk and Hemostasis

It should also be used cautiously in patients with heavy menstrual bleeding, bleeding disorders, or recent surgery, and reviewed with a doctor if taking warfarin or other anticoagulants or antiplatelet drugs. The antiplatelet mechanisms of the herb are well established at the pharmacological level and have clinical safety implications.

8.3 Warfarin and Anticoagulant Interactions

Research found that Conioselinum anthriscoides 'Chuanxiong' extract had inhibitory effects on CYP2C9 and CYP1A2, competitively inhibited metabolic enzymes, increased free warfarin, and increased the anticoagulant effect. CYP2C9 is the primary hepatic enzyme responsible for metabolizing the more pharmacologically active S-warfarin; inhibition of this enzyme by Chuanxiong constituents could meaningfully elevate circulating warfarin levels and bleeding risk.

A preparation (Shunaoxin Dripping Pills) composed of Ligusticum chuanxiong and Angelica sinensis can significantly reduce platelet aggregation induced by ADP and thrombin; high-dose combination with warfarin can significantly prolong activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT), suggesting that high-dose combination with warfarin can increase the anticoagulant effect.

8.4 General Adverse Event Profile in Trials

In the Chuanxiong Qingnao Granule randomized, double-blind, placebo-controlled trial (346 participants over 28 weeks), no severe adverse events were observed. In the systematic review of 19 RCTs on Chuanxiong formulae for migraine, adverse event monitoring was reported in 16 out of the 19 studies. The systematic reviews did not aggregate data sufficient to characterize specific adverse event types or frequencies in the sources accessed.

8.5 Quality Control Challenges

The current chemical markers in pharmacopoeias or monographs for the quality assessment of Szechwan lovage rhizome are not well characterized or specifically characterized, nor do they fully reflect the medicinal efficacy of the herb, resulting in quality not being effectively controlled. This means that the actual content of bioactive constituents — including TMP, ligustilide, and ferulic acid — can vary considerably between commercial preparations, complicating both dosing and safety assessments.

8.6 Phytoprogestogens

The plant contains the phytoprogestogens 3,8-dihydrodiligustilide and riligustilide. The physiological significance of these compounds in humans at typical dietary or supplemental exposure levels has not been established in the sources reviewed, but their presence is noted in the phytochemical literature.

References

• PMC / MDPI Pharmaceuticals — "Evaluation of the Pharmaceutical Activities of Chuanxiong, a Key Medicinal Material in Traditional Chinese Medicine" (2024)
• Frontiers in Pharmacology — "Ligusticum chuanxiong: a chemical, pharmacological and clinical review" (2025)
• Frontiers in Pharmacology — "Research Advances in Cardio-Cerebrovascular Diseases of Ligusticum chuanxiong Hort." (2022)
• PMC / Frontiers in Pharmacology — "Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials" (2018)
• PMC — "A Chinese Prescription Chuanxiong Chatiao San for Migraine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" (2019)
• PMC — "Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial" (2021)
• PMC — "Efficacy of Chuanxiong Ding Tong Herbal Formula Granule in the Treatment and Prophylactic of Migraine Patients: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial"
• PMC — "Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective" (2016)
• PMC — "Cardiovascular Actions and Therapeutic Potential of Tetramethylpyrazine (Active Component Isolated from Rhizoma Chuanxiong): Roles and Mechanisms" (2016)
• PMC — "Regulatory Mechanisms of Tetramethylpyrazine on Central Nervous System Diseases: A Review" (2022)
• PMC — "Meta-Analysis of the Clinical Effectiveness and Safety of Ligustrazine in Cerebral Infarction" (2016)
• PMC — "The Protective Effects and Potential Mechanisms of Ligusticum chuanxiong: Focus on Anti-Inflammatory, Antioxidant, and Antiapoptotic Activities" (2020)
• PMC — "Synergic Neuroprotection Between Ligusticum Chuanxiong Hort and Borneol Against Ischemic Stroke by Neurogenesis via Modulating Reactive Astrogliosis and Maintaining the Blood–Brain Barrier" (2021)
• PMC — "Ligusticum chuanxiong Hort. Ameliorates Neuropathic Pain by Regulating Microglial M1 Polarization: A Study Based on Network Pharmacology" (2024)
• PMC — "Ligusticum chuanxiong Hort as a medicinal and edible plant foods: Antioxidant, anti-aging and neuroprotective properties in Caenorhabditis elegans" (2022)
• PMC — "Effects of Tetramethylpyrazine on Functional Recovery and Neuronal Dendritic Plasticity after Experimental Stroke" (2015)
• PMC / Frontiers in Pharmacology — "Interaction Between Chinese Medicine and Warfarin: Clinical and Research Update" (2021)
• Pharmaceutical Biology (Taylor & Francis) — "Ligusticum chuanxiong Hort: A review of chemistry and pharmacology" (2011)
• PMC / Chinese Medicine (SpringerNature) — "The variation in the major constituents of the dried rhizome of Ligusticum chuanxiong (Chuanxiong) after herbal processing" (2016)
• PMC — "Exploring the Scientific Rationality of 'Different Dosage Forms of the Same Prescription' of Chinese Proprietary Medicine Based on Biopharmaceutical Properties of Powder and Pill of Chuanxiong Chatiao Prescription" (2022)
• PMC / IJMS — "Pharmacokinetic Comparison of Ferulic Acid in Normal and Blood Deficiency Rats after Oral Administration of Angelica sinensis, Ligusticum chuanxiong and Their Combination" (2012)
• PMC — "Preclinical evidence and mechanistic insights of ligustilide in ischemic stroke: a systematic review and meta-analysis" (2025)
• American Botanical Council HerbClip — "Szechuan Lovage" (2019)
• Wikipedia — "Conioselinum anthriscoides" (taxonomic reference)
• ScienceDirect Topics — "Ligusticum chuanxiong" (overview)